Management of invasive candidiasis in critically ill patients

Drugs

Volumn 64, Issue 19, 2004, Pages 2159-2175

  Blot, Stijn ^a   Vandewoude, Koenraad ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BILIRUBIN; CASPOFUNGIN; CORTICOSTEROID; CREATININE; CYCLODEXTRIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; HEAT SHOCK PROTEIN 90; ITRACONAZOLE; PLACEBO; PYRROLE DERIVATIVE; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VORICONAZOLE;

ACUTE HEMORRHAGIC PANCREATITIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BLOOD CULTURE; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHILL; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CRITICAL ILLNESS; DIAGNOSTIC ACCURACY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; LIVER FAILURE; LIVER TRANSPLANTATION; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT CARE; PROGNOSIS; REVIEW; RIGOR; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOPHLEBITIS; TREATMENT INDICATION; VOMITING;

ANTIFUNGAL AGENTS; BELGIUM; CANDIDIASIS; CRITICAL ILLNESS; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; RISK FACTORS;

CANDIDA;

EID: 6044247215     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464190-00002     Document Type: Review

References (132)

1. Daschner F. Nosocomial infections in intensive care units. Intensive Care Med 1985; 11: 284-7
2. Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med 1982; 10: 355-7
3. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91:72S-5S
4. Jarvis WR, Martone WJ. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 Suppl. A: 19-24
5. Holzheimer RG, Dralle H. Management of mycoses in surgical patients: review of the literature. Eur J Med Res 2002; 7: 200-26
6. Dean DA, Burchard KW. Fungal infection in surgical patients. Am J Surg 1996; 171: 374-82
7. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989: National Nosocomial Infections Surveillance System. Am J Med 1991; 91: 86S-9S
8. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70
9. Hobson RP. The global epidemiology of invasive Candida infections: is the tide turning? J Hosp Infect 2003; 55: 159-68
10. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992; 11:287-91
11. Sandven P, Bevanger L, Digranes A, et al. Constant low rate of fungemia in Norway, 1991 to 1996: the Norwegian Yeast Study Group. J Clin Microbiol 1998; 36: 3455-9
12. Kibbler CC, Seaton S, Barnes RA, et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003; 54: 18-24
13. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639-44
14. Voss A, le Noble JL, Verduyn Lunel FM, et al. Candidemia in intensive care unit patients: risk factors for mortality. Infection 1997; 25: 8-11
15. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23: 23-30
16. Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-16
17. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35: 627-30
18. Monitoring hospital-acquired infections to promote patient safety: United States, 1990-1999. MMWR Morb Mortal Wkly Rep 2000; 49: 149-53
19. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247-51
20. Eubanks PJ, de Virgilio C, Klein S, et al. Candida sepsis in surgical patients. Am J Surg 1993; 166: 617-9
21. Garbino J, Kolarova L, Rohner P, et al. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81: 425-33
22. Lipman J, Saadia R. Fungal infections in critically ill patients. BMJ 1997; 315: 266-7
23. Nguyen MH, Peacock Jr JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-23
24. Blot S, Vandewoude K, Hoste E, et al. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata. J Hosp Infect 2001; 47: 308-13
25. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96: 2055-61
26. Marr KA, Seidel K, White TC, et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16
27. Slotman GJ, Shapiro E, Moffa SM. Fungal sepsis: multisite colonization versus fungemia. Am Surg 1994; 60: 107-13
28. Cornwell III EE, Belzberg H, Berne TV, et al. The pattern of fungal infections in critically ill surgical patients. Am Surg 1995; 61: 847-50
29. Ekenna O, Sherertz RJ, Bingham H. Natural history of bloodstream infections in a burn patient population: the importance of candidemia. Am J Infect Control 1993; 21: 189-95
30. Blot SI, Vandewoude KH, Hoste EA, et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002; 113: 480-5
31. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21
32. McKinnon PS, Goff DA, Kern JW, et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. Arch Surg 2001; 136: 1401-8
33. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86
34. Rex JH. Editorial response: catheters and candidemia. Clin Infect Dis 1996; 22; 467-70
35. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 1989; 149: 2349-53
36. Bradley JA, Hamilton DN, Brown MW, et al. Cellular defense in critically ill surgical patients. Crit Care Med 1984; 12: 565-70
37. Borzotta AP, Beardsley K. Candida infections in critically ill trauma patients: a retrospective case-control study. Arch Surg 1999; 134: 657-64
38. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3: 1541-54
39. Vanholder R, Van Biesen W. Incidence of infectious morbidity and mortality in dialysis patients. Blood Purif 2002; 20: 477-80
40. Turner PC, Humphreys H. Hemofiltration: treating and preventing infection. Clin Microbiol Infect 1996; 2: 80-5
41. Hoste E, Blot S, Lameire N, et al. Impact of nosocomial bloodstream infection on the outcome of critically ill patients with acute renal failure treated with renal replacement therapy. J Am Soc Nephrol 2004; 15: 454-62
42. Takahashi K, Kita E, Konishi M, et al. Translocation model of Candida albicans in DB A-2/J mice with protein calorie malnutrition mimics hematogenous candidiasis in humans. Microb Pathog 2003; 35: 179-87
43. Gianotti L, Alexander JW, Fukushima R, et al. Translocation of Candida albicans is related to the blood flow of individual intestinal villi. Circ Shock 1993; 40: 250-7
44. Krause W, Matheis H, Wulf K. Fungaemia and funguria after oral administration of Candida albicans. Lancet 1969; I: 598-9
45. Pittet D, Monod M, Suter PM, et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8
46. Bross J, Talbot GH, Maislin G, et al. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989; 87: 614-20
47. Garbino J, Lew DP, Romand JA, et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28: 1708-17
48. Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772-85
49. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5
50. Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002; 21: 767-74
51. Alonso-Valle H, Acha O, Garcia-Palomo JD, et al. Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003; 22: 254-7
52. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7
53. Michalopoulos AS, Geroulanos S, Mentzelopoulos SD. Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients. Chest 2003; 124: 2244-55
54. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17: 168-75
55. Charles PE, Doise JM, Quenot JP, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med 2003; 29: 2162-9
56. Blot SI, Vandewoude KH. Estimating attributable mortality of candidemia: clinical judgement vs matched cohort studies. Eur J Clin Microbiol Infect Dis 2003; 22: 132-3
57. Wenzel RP. The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? Int J Epidemiol 1988; 17: 225-7
58. Blot SI, Hoste EA, Vandewoude KH, et al. Estimates of attributable mortality of systemic Candida infection in the ICU. J Crit Care 2003; 18: 130-1
59. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43
60. Anaissie EJ, Rex JH, Uzun O, et al. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104: 238-45
61. Solomkin JS. Pathogenesis and management of Candida infection syndromes in non-neutropenic patients. New Horiz 1993; 1: 202-13
62. Blot S, Vandewoude K. Early detection of systemic infections. Acta Clin Belg 2004; 59: 20-3
63. Donahue SP. Intraocular candidiasis in patients with candidemia. Ophthalmology 1998; 105: 759-60
64. Wingard JR. Lipid formulations of amphotericins: are you a lumper or a splitter? Clin Infect Dis 2002; 35: 891-5
65. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89
66. Bekersky I, Fielding RM, Dressier DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834-40
67. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 1325-30
68. Voss A, de Pauw BE. High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis 1999; 18: 165-74
69. Duswald KH, Penk A, Pittrow L. High-dose therapy with fluconazole > or = 800mg day-1. Mycoses 1997; 40: 267-77
70. Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41: 2714-8
71. Kam LW, Lin JD. Management of systemic candidal infections in the intensive care unit. Am J Health Syst Pharm 2002; 59: 33-41
72. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, et al. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22; 651-5
73. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35
74. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-9
75. Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multi center study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-7
76. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9
77. Patel R. Antifungal agents. Part I: amphotericin B preparations and flucytosine. Mayo Clin Proc 1998; 73: 1205-25
78. Flanagan PG, Barnes RA. Fungal infection in the intensive care unit. J Hosp Infect 1998; 38: 163-77
79. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51
80. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-37
81. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72
82. De Waele JJ, Vogelaers D, Blot S, et al. Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003; 37: 208-13
83. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20: 1531-4
84. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003; 3: 685-702
85. Chen YC, Chang SC, Luh KT, et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52: 71-7
86. Harbarth S, Burke JP, Lloyd JF, et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002; 35: e120-7
87. Hoste EA, Lameire NH, Vanholder RC, et al. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. J Am Soc Nephrol 2003; 14: 1022-30
88. Hoste E, Decruyenaere J, Colardyn F. Biocompatibility and acute renal failure. Lancet 2000; 355: 312-3
89. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-72
90. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71
91. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34
92. Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13: 930-1
93. Benoit JL, Carandang G, Sitrin M, et al. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995; 21: 1286-8
94. Viale P, Petrosillo N, Signorini L, et al. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin Infect Dis 2001; 33: 1947-8
95. British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994; 20: 522-8
96. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia: NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21: 994-6
97. Oude Lashof AM, Donnelly JP, Meis JF, et al. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis 2003; 22: 43-8
98. Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest 2002; 122: 302-10
99. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96: 200-9
100. Benoit D, Decruyenaere J, Vandewoude K, et al. Management of candidal thrombophlebitis of the central veins: case report and review. Clin Infect Dis 1998; 26: 393-7
101. Rabinovici R, Szewczyk D, Ovadia P, et al. Candida pericarditis: clinical profile and treatment. Ann Thorac Surg 1997; 63: 1200-4
102. Vikram HR, Buenconsejo J, Hasbun R, et al. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA 2003; 290: 3207-14
103. Baddour LM. Long-term suppressive therapy for Candida parapsilosis-induced prosthetic valve endocarditis. Mayo Clin Proc 1995; 70: 773-5
104. Johnston PG, Lee J, Domanski M, et al. Late recurrent Candida endocarditis. Chest 1991; 99: 1531-3
105. Sawyer RG, Rosenlof LK, Adams RB, et al. Peritonitis into the 1990s: changing pathogens and changing strategies in the critically ill. Am Surg 1992; 58: 82-7
106. Nathens AB, Rotstein OD, Marshall JC. Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 1998; 22; 158-63
107. Rotstein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg 1986; 29: 247-50
108. Sotto A, Lefrant JY, Fabbro-Peray P, et al. Evaluation of antimicrobial therapy management of 120 consecutive patients with secondary peritonitis. J Antimicrob Chemother 2002; 50: 569-76
109. Aloia T, Solomkin J, Fink AS, et al. Candida in pancreatic infection: a clinical experience. Am Surg 1994; 60: 793-6
110. Sandven P, Qvist H, Skovlund E, et al. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30: 541-7
111. Sandven P, Giercksky KE. Yeast colonization in surgical patients with intra-abdominal perforations. Eur J Clin Microbiol Infect Dis 2001; 20: 475-81
112. Adamson PC, Rinaldi MG, Pizzo PA, et al. Amphotericin B in the treatment of Candida cholecystitis. Pediatr Infect Dis J 1989; 8: 408-11
113. Kozinin PJ, Taschdjian CL, Goldberg PK, et al. Advances in the diagnosis of renal candidiasis. J Urol 1978; 119: 184-7
114. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30: 19-24
115. Sobel JD, Lundstrom T. Management of candiduria. Curr Urol Rep 2001; 2: 321-5
116. Kontoyiannis DP, Luna MA, Samuels BI, et al. Hepatosplenic candidiasis: a manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14: 721-39
117. Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41: 1944-8
118. Walsh TJ, Whitcomb PO, Revankar SG, et al. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76: 2357-62
119. Kauffman CA, Bradley SF, Ross SC, et al. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91: 137-41
120. Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108: 88-100
121. Helton WS, Carrico CJ, Zaveruha PA, et al. Diagnosis and treatment of splenic fungal abscesses in the immune-suppressed patient. Arch Surg 1986; 121: 580-6
122. Sanchez-Portocarrero J, Perez-Cecilia E, Roca V, et al. Candida albicans meningitis in 2 parenteral drug addicts: review of the literature. Enferm Infecc Microbiol Clin 1993; 11: 244-9
123. Nguyen MH, Yu VL. Meningitis caused by Candida species: an emerging problem in neurosurgical patients. Clin Infect Dis 1995; 21: 323-7
124. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis: Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78
125. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis: National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 291-6
126. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-32
127. Lew TW, Darby J, Marion DW. Candida mediastinitis and septic shock following occult esophageal perforation in a patient with posttraumatic quadriplegia. J Trauma 1995; 39: 805-8
128. Glower DD, Douglas Jr JM, Gaynor JW, et al. Candida mediastinitis after a cardiac operation. Ann Thorac Surg 1990; 49: 157-63
129. Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004 Apr; 23 (4): 256-70
130. Vazquez JA. Combination antifungal therapy against Candida species: the new frontier - are we there yet? Med Mycol 2003; 41: 355-68
131. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48: 693-715
132. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-16